16 results about "Acetyltransferase" patented technology

This invention provides an engineered bacterium for producing ectoine, its preparation method, and its application. The engineered bacterium is prepared using a method comprising the following steps: using *Corynebacterium glutamicum* as the starting strain, feedback inhibition by aspartate kinase LysC is relieved, the activity of the gene lysE encoding lysine efflux permease is reduced, and the ectoine synthesis gene cluster ectABC is expressed. Based on this, the activity of any one or at least two of the following—diaminobutyrate acetyltransferase EctA, pyruvate carboxylase Pyc, or aspartate kinase LysC—is enhanced, and / or the activity of any one or at least two of the following—maloquinone oxidoreductase Mqo or homoserine dehydrogenase Hom—is reduced to further increase ectoine yield.

This invention discloses an engineered bacterium that efficiently catalyzes the synthesis of N-acetyl-natamycin and its applications, belonging to the fields of biocatalysis and enzyme engineering technology. This invention also provides an N-acetyltransferase mutant. Mt GNAT W289A / S121G This mutant, obtained through targeted modification, can catalyze the synthesis of N-acetyl-natamycin using natamycin as a substrate and acetyl-CoA as an acetyl donor. After fed-batch fermentation, the wet cell yield reached 124.8 g / L. In a 1 L reaction system using a 30 g / L catalyst, the N-acetyl-natamycin yield reached 31.2 g / L, with a conversion rate of 90.2%. The wet cells obtained from 1 L of fermentation could catalyze four batches of reactions, yielding a cumulative total of 122.3 g of N-acetyl-natamycin. This invention features mild reaction conditions, high selectivity, and few byproducts, making it suitable for the efficient preparation of N-acetyl-natamycin.

The present application relates to the technical field of genetic engineering, and discloses a recombinant Escherichia coli for high-yield O-acetyl-L-homoserine and application thereof. The recombinant Escherichia coli for high-yield O-acetyl-L-homoserine is obtained by the following combination of modification strategies: in Escherichia coli W3110, a gene encoding homoserine O-acetyltransferase is integrated into a gene site encoding L-arginine ABC transporter ATP binding subunit, then a gene encoding phosphoacetyltransferase is knocked out, then a gene encoding transcriptional anti-terminator and mRNA stability regulator is knocked out, then a gene encoding ATP-NAD kinase is integrated into a gene site encoding NADPH-dependent aldehyde reductase, and finally a gene promoter of acetyl-CoA synthetase is replaced by a Ptrc promoter to obtain the recombinant Escherichia coli. The recombinant Escherichia coli is used for fermentation to produce O-acetyl-L-homoserine, and has the advantage of high yield. metx artp patz cspc ppnk yahk acs ​​​​​​​

This invention relates to the construction and staining application of recombinant Escherichia coli for synthesizing indoleacetic acid ester. The recombinant Escherichia coli for synthesizing indoleacetic acid ester is obtained by using recombinant Escherichia coli MG1655ΔpheAΔtrpRΔtyrAΔyddGΔarsB::tac70-MaFMOΔldhA::tac70-MaFMOΔyghWX::tac70-tnaAΔpoxB::tac70-cav1 as the initial strain. Then, the endogenous acetylesterase is knocked out, and the endogenous tryptophan hydrolase gene tnaA and the flavin monooxygenase gene maFMO are overexpressed, while simultaneously overexpressing the acetyltransferase gene. The indoleacetic acid ester yield of this invention is as high as 195.3 mg / L. Using indoleacetic acid ester for staining eliminates the need for reducing agents and enzyme solutions, significantly reducing staining costs.

This invention discloses a genetically engineered bacterium lacking the acetyltransferase gene asp12, its construction method, and its applications. This invention utilizes CRISPR / Cas9 to knock out the asp12 gene encoding acetyltransferase in Aspergillus terreus strain GZU-31-1, constructing the genetically engineered bacterium Δasp12. This invention found that compared to the wild-type Aspergillus terreus strain GZU-31-1, the genetically engineered bacterium Δasp12 exhibits increased accumulation and significantly higher yield of the compound Aspermeroterpene F, which possesses anti-inflammatory and anti-hepatic fibrosis activities. Based on the genetically engineered bacterium Δasp12, this invention also provides a method for preparing the compound Aspermeroterpene F, further improving the yield of the compound by optimizing the fermentation culture medium. This invention is beneficial for the development of anti-inflammatory and anti-hepatic fibrosis drugs.

The present invention is related to production of retinyl acetate generated via enzymatic conversion of retinol, said process including the use of modified enzymes with improved activity.

This invention discloses a 2,6,10,14-tetramethylpentadecane derivative compound, its preparation method, and its applications. The structure of the compound is shown in formula (I). Compared with natural 2,6,10,14-tetramethylpentadecane, the compound has significantly enhanced binding ability to the malonyl / acetyltransferase functional domain (MAT) of fatty acid synthase (FASN), significantly enhanced ability to inhibit fatty acid synthesis, significantly enhanced therapeutic effect on diseases related to FASN abnormalities, significantly enhanced activation of anti-tumor immunity, and significantly enhanced inhibition of tumor growth. It can be effectively used in the preparation of drugs that inhibit fatty acid synthesis, drugs that treat fatty acid synthesis abnormalities, cancer treatment drugs, and immunotherapy drugs.

This invention discloses an acetyltransferase ARD1 inhibitor, D753-0266, and its application in the treatment of colorectal cancer, belonging to the field of biomedical technology. Through molecular dynamics simulations and binding energy calculations, it was found that the binding energy of D753-0266 to NAA10 can reach -68.12 kcal / mol. In vitro experiments show that D753-0266 can directly bind to and stabilize the ARD1 protein, downregulate its expression level, and dose-dependently inhibit the proliferation of colorectal cancer cells, while significantly inhibiting cell migration and colony formation. In vivo experiments show that D753-0266 effectively inhibits tumor growth in a mouse xenograft model and is well-tolerated. This inhibitor fills a research gap in the field of ARD1 targeting and can be used to prepare colorectal cancer therapeutic drugs, possessing high specificity and clinical translational potential.

This invention discloses a method for heterologous production of 7-aminodeacetoxycephalosporanic acid using *Aspergillus nidulans*. This invention targets a *Aspergillus nidulans* strain that heterologously produces 7-aminodeacetoxycephalosporanic acid. Genes derived from the biosynthetic gene clusters pcbAB / C, isopentine N-acetyltransferase gene, and cefE gene, or their mutants, are assembled into a *Aspergillus nidulans* expression vector. Co-expression is performed in a *Aspergillus nidulans* basal cell strain to obtain a recombinant strain, successfully achieving heterologous expression of 7-aminodeacetoxycephalosporanic acid in filamentous fungi. Experiments show that the yield can reach 0.13 g / L at the shake-flask level. The strain constructed in this invention provides a good heterologous expression system for studying the synthesis and regulatory mechanism of 7-aminodeacetoxycephalosporanic acid.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

The application discloses a kind of simultaneously resistant glufosinate and 2,4-D class herbicide fusion gene, expression vector and application, the core innovation of the application is in that first aromatic oxyalkanoic acid dioxygenase gene, glufosinate acetyltransferase gene is functionally fused, constructs a kind of new herbicide-resistant fusion gene, the gene not only can simultaneously give plant to glufosinate and 2,4-D class herbicide double resistance, also makes resistance level compared to single gene expression respectively increases by 8%-10%, and under high expression condition, the inhibition rate of plant growth is reduced by about 15%, significantly widen the selection range of field herbicide, improve the safety and profitability of crop planting.

The application provides a saccharomyces cerevisiae engineering bacterium for producing squalene through endogenous and artificial synthetic pathways and an application thereof, the saccharomyces cerevisiae engineering bacterium takes ZS00 strain as a starting strain, overexpresses acetyl coenzyme A acetyltransferase gene, hydroxymethylglutaryl coenzyme A synthase gene and N-terminal truncated hydroxymethylglutaryl coenzyme A reductase gene, and effectively improves the yield of squalene. Heterologous expression of mevalonate kinase gene and mevalonate pyrophosphate decarboxylase gene, overexpression of the key gene squalene synthase gene for promoting the conversion of precursors into squalene effectively promotes the synthesis of squalene. The introduction of isopentenol utilization pathway genes and their mutants, through the regulation of IU pathway key substrate, overexpression of isopentenyl pyrophosphate isomerase gene and farnesyl pyrophosphate synthase gene, the final strain can effectively accumulate squalene to 687.93 mg / L. The application realizes the breakthrough of squalene yield and efficiency through complementation and synergistic effect.

This invention discloses a reagent for inhibiting Acetyl-CoA or GCN5 acetyltransferase and its application, belonging to the field of biomedical technology; a drug comprising a reagent capable of inhibiting Acetyl-CoA synthesis or GCN5 inhibition; tumor stem cells interact with T cells, and T cells can obtain a large amount of Acetyl-CoA from tumor stem cells; Acetyl-CoA, as an acetylation substrate, can acetylate Blimp-1 under the action of GCN5 acetyltransferase, downregulating Blimp-1 expression, thereby inhibiting TRM cell differentiation; by targeting and inhibiting Acetyl-CoA synthesis and GCN5 inhibition, Blimp-1 expression is upregulated, TRM cell differentiation is maintained, and the body's anti-tumor ability is improved; the Acetyl-CoA and GCN5 provided by this invention provide new targets for the treatment of NSCLC.

This specification describes the crystalline form of the small molecule lysine acetyltransferase 6A (KAT6A) inhibitor: Compound 1, as well as its pharmaceutical composition and methods of use in the treatment of diseases or conditions for which treatment with the lysine acetyltransferase 6A (KAT6A) inhibitor is beneficial. [Formula 1] JPEG2026516755000035.jpg4268

The application belongs to the field of pharmaceutical chemistry, and particularly relates to a method for biosynthesizing lanatoside C based on acetyltransferase to deacetylcardiopine, the application obtains soluble target protein with a purity of >90%, at least one candidate enzyme can catalyze the generation of lanatoside C, and the product can be confirmed by HPLC and LC-MS. The optimal reaction condition of each enzyme is obtained, and the target conversion rate is >50%. The Km and Vmax values of the best active enzyme are obtained, and the affinity and catalytic efficiency of the enzyme and the substrate are evaluated.

The application discloses a recombinant engineering bacterium with ThlA gene knockout and industrial gas source domestication and application thereof. The recombinant engineering bacterium is Clostridium autoethanogenum engineering bacterium with the preservation number of GDMCC No: 67962. The application optimizes carbon flow distribution of the C. autoethanogenum from the metabolic pathway level by using the CRISPR / Cas9 gene editing technology to knock out the acetyl coenzyme A acetyltransferase coding gene ThlA (gene number: CLAU_0409), and reduces by-product generation. On this basis, the gene edited strain is further subjected to laboratory directional domestication to strengthen the tolerance and adaptability of the strain to the complex environment of steel industry tail gas, and finally the growth rate, ethanol selectivity and ethanol yield of the strain are simultaneously improved, thereby providing core strain support for industrialization landing of resource utilization of the steel industry tail gas.